Literature DB >> 26132376

Non-Alcoholic Fatty Liver Disease (NAFLD) in children and adolescents with Prader-Willi Syndrome (PWS).

D Fintini1, E Inzaghi2,3, M Colajacomo4, S Bocchini1, G Grugni5, C Brufani2, M Cappa2, V Nobili6, S Cianfarani3,7, A Crinò1.   

Abstract

We tested the hypothesis that patients with Prader-Willi syndrome (PWS) may be at lower risk of developing non-alcoholic fatty liver disease (NAFLD) because of a higher insulin sensitivity. Twenty-one PWS patients and 42 control subjects closely similar for age, gender, pubertal stage and body mass index (CNT), were studied. Metabolic profile and body composition were assessed. NAFLD was established by a validated method of US grading (range from G0 to G3). PWS patients showed a significantly better metabolic profile (lower waist circumference, fasting glucose levels, HOMA-IR, cholesterol, transaminase levels and trunk fat mass/fat mass ratio). Furthermore, NAFLD G1stage was significantly more frequent in PWS subjects (P < 0.05), whereas G2 stage was significantly more frequent in control patients (P < 0.05). NAFLD grading seems to correlate with body composition in PWS, also after adjustment for sex and GH treatment. To our knowledge, this is the first report suggesting a reduced risk of NAFLD in PWS children.
© 2015 World Obesity.

Entities:  

Keywords:  NAFLD; Prader-Willi; obesity; paediatric

Mesh:

Substances:

Year:  2015        PMID: 26132376     DOI: 10.1111/ijpo.12052

Source DB:  PubMed          Journal:  Pediatr Obes        ISSN: 2047-6302            Impact factor:   4.000


  6 in total

Review 1.  Review of Prader-Willi syndrome: the endocrine approach.

Authors:  Ryan Heksch; Manmohan Kamboj; Kathryn Anglin; Kathryn Obrynba
Journal:  Transl Pediatr       Date:  2017-10

2.  Angiopoietin-like 8 (ANGPTL8) as a potential predictor of NAFLD in paediatric patients with Prader-Willi Syndrome.

Authors:  C Mele; A Crinò; D Fintini; S Mai; A Convertino; S Bocchini; P Di Paolo; G Grugni; G Aimaretti; M Scacchi; P Marzullo
Journal:  J Endocrinol Invest       Date:  2020-10-16       Impact factor: 4.256

Review 3.  Do patients with Prader-Willi syndrome have favorable glucose metabolism?

Authors:  Yanjie Qian; Fangling Xia; Yiming Zuo; Mianling Zhong; Lili Yang; Yonghui Jiang; Chaochun Zou
Journal:  Orphanet J Rare Dis       Date:  2022-05-07       Impact factor: 4.303

4.  Circulating microRNA Associated to Different Stages of Liver Steatosis in Prader-Willi Syndrome and Non-Syndromic Obesity.

Authors:  Muhammad Yogi Pratama; Devis Pascut; Sofia Tamini; Alessandro Minocci; Claudio Tiribelli; Graziano Grugni; Alessandro Sartorio
Journal:  J Clin Med       Date:  2020-04-14       Impact factor: 4.241

5.  Differences in circulating microRNA signature in Prader-Willi syndrome and non-syndromic obesity.

Authors:  Devis Pascut; Sofia Tamini; Silvia Bresolin; Pablo Giraudi; Giuseppe Basso; Alessandro Minocci; Claudio Tiribelli; Graziano Grugni; Alessandro Sartorio
Journal:  Endocr Connect       Date:  2018-12-01       Impact factor: 3.335

6.  Growth hormone treatment for adults with Prader-Willi syndrome: another point of view.

Authors:  Harry J Hirsch; Varda Gross-Tsur
Journal:  Orphanet J Rare Dis       Date:  2021-08-03       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.